Effects of unilateral strength training and detraining on bone mineral density and content in young women: A study of mechanical loading and deloading on human bones

1994 ◽  
Vol 55 (1) ◽  
pp. 59-67 ◽  
Author(s):  
I. Vuori ◽  
A. Heinonen ◽  
H. Siev�nen ◽  
P. Kannus ◽  
M. Pasanen ◽  
...  
2003 ◽  
Vol 35 (Supplement 1) ◽  
pp. S77
Author(s):  
L E. Miller ◽  
S M. Nickols-Richardson ◽  
D F. Wootten ◽  
L M. Pierson ◽  
W K. Ramp ◽  
...  

2006 ◽  
Vol 20 (5) ◽  
Author(s):  
Michael T.C. Liang ◽  
Sara B Arnaud ◽  
Stanley L Bassin ◽  
Darren Dutto ◽  
William A Braun ◽  
...  

2012 ◽  
Vol 25 (3) ◽  
pp. 331-340 ◽  
Author(s):  
Susan Ziglar ◽  
Tracy S. Hunter

Maximizing bone mass in youth is touted as the best strategy to offset the natural losses of aging and the menopausal transition. Not achieving maximum peak bone mineral density (BMD) is an independent risk factor for osteoporosis and thus a public health concern. Adolescence is a critical time of bone mineralization mediated by endogenous estradiol. Research has shown that the highest velocity of bone mass accrual occurs 1 year before menarche and after the first 3 years. Low-peak attainment of BMD in young women is associated with contributing factors such as diets low in calcium, eating disorders, lack of exercise, smoking, and low estrogen states. Oral contraceptives (OCs) suppress endogenous estradiol production by suppressing the hypothalamic–pituitary–ovarian axis. Thus, OCs, by replacing endogenous estradiol with ethinyl estradiol (EE), establish and maintain new hormone levels. The early initiation and the use of very low dose of EE raises the possibility that bone mass accrual at a critical time of bone mineralization in young women or adolescents may be jeopardized. This review examines the studies of BMD in adolescents and young women that use combination hormonal contraception. Some studies had inherent limitations, such as small trial, poor control of confounders, failure to exclude women with prior use of hormonal contraceptives, or prior pregnancy from control groups. The vast majority of reviewed studies showed OCs containing 20 to 30 µg of EE interfere with acquisition of peak BMD. Limited numbers of studies examine the effects of OCs containing 35 µg on adolescents and young adults. Additionally, studies are needed evaluating the progestin component of OCs as their differing androgenic properties may affect bone mineralization as well.


1998 ◽  
Vol 68 (3) ◽  
pp. 749-754 ◽  
Author(s):  
D Teegarden ◽  
R M Lyle ◽  
G P McCabe ◽  
L D McCabe ◽  
W R Proulx ◽  
...  

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Jeannette Michele Beasley ◽  
Laura E Ichikawa ◽  
Brett A. Ange ◽  
Leslie Spangler ◽  
Andrea Z LaCroix ◽  
...  

2002 ◽  
Vol 93 (6) ◽  
pp. 2034-2037 ◽  
Author(s):  
H. Cavalié ◽  
G. Lac ◽  
P. Lebecque ◽  
B. Chanteranne ◽  
M.-J. Davicco ◽  
...  

This paper reports that the selective β2-adrenergic receptor agonist clenbuterol affects bone metabolism in growing 3-mo-old male Wistar rats treated over 8 wk. Thirty-two 3-mo-old growing Wistar rats weighing 234 ± 2 g were assigned to a progressive isometric force, strength-training exercise program plus oral clenbuterol (2 mg · kg body wt−1 · day−1) for 5 days each week, exercise program without clenbuterol 5 days each week, no exercise program plus oral clenbuterol (2 mg · kg−1 · day−1) for 5 days each week, or no exercise without clenbuterol 5 days each week. At the end of 8 wk, lean mass, fat mass, and right total femoral, distal metaphyseal femoral, and diaphyseal femoral bone mineral density were measured by Hologic QDR 4500 dual X-ray absorptiometry (DEXA) technique. Left femoral bones were harvested after death on day 58, and femoral resistance was determined by three-point bending testing. We found that fat mass was decreased in rats given strength training exercise and decreased further in rats treated with clenbuterol. Lean mass was increased in clenbuterol-treated animals. Strength-training exercise appeared to have no effect on bone mineral density, serum osteocalcin, or urinary deoxypyridinoline. However, clenbuterol treatment decreased femoral length, diameter, bone mineral density, and mechanical resistance. Clenbuterol had no effect on osteocalcin but increased urinary deoxypyridinoline. We concluded that clenbuterol treatment decreased bone mineral density and increased bone resorption independent of the level of exercise rats were given.


2011 ◽  
Vol 89 (3) ◽  
pp. 228-233 ◽  
Author(s):  
Gabriella Milos ◽  
Luigi M. Gallo ◽  
Branca Sosic ◽  
Daniel Uebelhart ◽  
Gerhard Goerres ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document